AU2001245628A1 - Immunomodulatory formulations and methods for use thereof - Google Patents

Immunomodulatory formulations and methods for use thereof

Info

Publication number
AU2001245628A1
AU2001245628A1 AU2001245628A AU2001245628A AU2001245628A1 AU 2001245628 A1 AU2001245628 A1 AU 2001245628A1 AU 2001245628 A AU2001245628 A AU 2001245628A AU 2001245628 A AU2001245628 A AU 2001245628A AU 2001245628 A1 AU2001245628 A1 AU 2001245628A1
Authority
AU
Australia
Prior art keywords
methods
use
immunomodulatory formulations
immunomodulatory
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001245628A
Other versions
AU2001245628B2 (en
Inventor
Stephen Tuck
Gary Van Nest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US18855700P priority Critical
Priority to US60/188,557 priority
Priority to US09/802,376 priority patent/US7129222B2/en
Priority to US09/802,376 priority
Application filed by Dynavax Technologies Corporation filed Critical Dynavax Technologies Corporation
Priority to PCT/US2001/007843 priority patent/WO2001068143A2/en
Publication of AU2001245628A1 publication Critical patent/AU2001245628A1/en
Application granted granted Critical
Publication of AU2001245628B2 publication Critical patent/AU2001245628B2/en
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2001245628A 2000-03-10 2001-03-12 Immunomodulatory formulations and methods for use thereof Ceased AU2001245628B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US18855700P true 2000-03-10 2000-03-10
US60/188,557 2000-03-10
US09/802,376 US7129222B2 (en) 2000-03-10 2001-03-09 Immunomodulatory formulations and methods for use thereof
US09/802,376 2001-03-09
PCT/US2001/007843 WO2001068143A2 (en) 2000-03-10 2001-03-12 Immunomodulatory formulations and methods for use thereof

Publications (2)

Publication Number Publication Date
AU2001245628A1 true AU2001245628A1 (en) 2001-12-06
AU2001245628B2 AU2001245628B2 (en) 2005-11-10

Family

ID=40568742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4562801A Pending AU4562801A (en) 2000-03-10 2001-03-12 Immunomodulatory formulations and methods for use thereof
AU2001245628A Ceased AU2001245628B2 (en) 2000-03-10 2001-03-12 Immunomodulatory formulations and methods for use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU4562801A Pending AU4562801A (en) 2000-03-10 2001-03-12 Immunomodulatory formulations and methods for use thereof

Country Status (9)

Country Link
US (3) US7129222B2 (en)
EP (2) EP1261377B1 (en)
JP (1) JP2004502645A (en)
AT (1) AT441436T (en)
AU (2) AU4562801A (en)
CA (1) CA2402294A1 (en)
DE (1) DE60139764D1 (en)
DK (1) DK1261377T3 (en)
WO (1) WO2001068143A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69739515D1 (en) * 1996-01-30 2009-09-10 Univ California Expression vectors inducing an antigen-specific immune response and methods for their use.
EP0855184A1 (en) * 1997-01-23 1998-07-29 Klaus Prof.-Dr. Heeg Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
PT1077722E (en) * 1998-05-22 2006-12-29 Coley Pharm Group Inc Methods and products for inducing mucosal immunity
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AT378348T (en) * 2000-01-14 2007-11-15 Us Health Oligode oxynucleotides and their use for inducing an immune reaction
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030199466A1 (en) * 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
US20040132677A1 (en) * 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
KR20040019069A (en) * 2001-07-20 2004-03-04 인터뮨, 인크. Methods of treating liver fibrosis
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
JP4607452B2 (en) * 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション Immunomodulating composition, formulation and method of use thereof
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP1356826A1 (en) * 2002-04-22 2003-10-29 BIOMAY Produktions- und Handels- Aktiengesellschaft Microparticles comprising carbohydrate beads covalently linked with allergen
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004014322A2 (en) * 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Immunostimulatory Nucleic Acids
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP1572122A4 (en) * 2002-11-01 2008-04-09 Us Gov Health & Human Serv Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ,インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK1575977T3 (en) 2002-12-23 2009-11-09 Dynavax Tech Corp Immunostimulatory sequence oligonucleotides and methods for using them
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
JP2007537284A (en) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド Nucleic acid microspheres, their production and delivery
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CN101160401A (en) * 2005-02-24 2008-04-09 科勒制药集团公司;科勒制药有限公司 Immunostimulatory oligonucleotides
WO2006096497A2 (en) * 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1764369A1 (en) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vaccines comprising truncated HBC core protein plus saponin-based adjuvant
PT1991678E (en) * 2006-02-15 2015-11-25 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonucleotide formulations
ES2555544T3 (en) * 2006-03-07 2016-01-04 Vaxinnate Corporation Compositions that include hemagglutinin, preparation methods and methods of use thereof
PT2078080E (en) * 2006-09-27 2015-09-18 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US20140024818A1 (en) * 2006-11-14 2014-01-23 Yi Lu Alignment of nanomaterials and micromaterials
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
EP2209476A4 (en) 2007-04-19 2011-01-19 Univ Pittsburgh Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20110020388A1 (en) 2009-05-27 2011-01-27 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
BR112012005349A2 (en) * 2009-09-09 2016-03-29 Matrivax Res & Dev Corp immunogenic composition, its method of manufacture, method of manufacturing a protein matrix vaccine composition, and use
PL2575876T3 (en) 2010-05-26 2018-07-31 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
BR112012030337A2 (en) * 2010-05-28 2017-01-24 Coley Pharm Group Inc vaccines comprising cholesterol and cpg as exclusive carrier-adjuvant molecules and use thereof
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
KR101670340B1 (en) * 2011-05-18 2016-10-28 매트리백스 인코포레이티드 Protein matrix vaccine compositions including polycations
RU2480206C1 (en) * 2012-04-17 2013-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Министерства здравоохранения и социального развития Российской Федерации" Method of immunocorrection of main course of treatment of destructive forms of pulmonary tuberculosis
WO2014052453A1 (en) 2012-09-25 2014-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
PL3164113T3 (en) 2014-06-04 2019-09-30 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3223104A1 (en) 1982-06-21 1983-12-22 Hoechst Ag Photopolymerizable mixture and thus produced photopolymerizable copying material
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5629158A (en) * 1989-03-22 1997-05-13 Cemu Bitecknik Ab Solid phase diagnosis of medical conditions
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
ES2115343T3 (en) * 1993-11-05 1998-06-16 Amgen Inc Method of preparing liposomes and encapsulating material.
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5869715A (en) * 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
DE69739515D1 (en) 1996-01-30 2009-09-10 Univ California Expression vectors inducing an antigen-specific immune response and methods for their use.
AU4043497A (en) 1996-07-29 1998-02-20 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California Immuno stimulator polinucleotide conjugates / immunomodulator molecula.
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
WO1998052962A1 (en) 1997-05-19 1998-11-26 Merck & Co., Inc. Oligonucleotide adjuvant
CA2301575C (en) 1997-05-20 2003-12-23 Heather L. Davis Vectors and methods for immunization or therapeutic protocols
US5971030A (en) * 1997-06-06 1999-10-26 Maimets; Lembit Apparatus and method for repairing pressure pipes and for securing other elements with a curable sealant
US6225292B1 (en) 1997-06-06 2001-05-01 The Regents Of The University Of California Inhibitors of DNA immunostimulatory sequence activity
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE69837094T2 (en) 1997-09-05 2007-08-30 The Regents Of The University Of California, Oakland Use of immune-related oligonucleotides for preventing or treating asthma
ES2175668T3 (en) 1997-12-16 2002-11-16 Chiron Corp Use of microparticles in combination with submicron oil-in-water.
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CA2333854A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereoisomers of cpg oligonucleotides and related methods
DK1112083T3 (en) * 1998-09-09 2004-03-08 Univ Washington Treatment of microvascular angiopathies
CA2343052A1 (en) 1998-09-18 2000-03-30 Dynavax Technologies Corporation Methods of treating ige-associated disorders and compositions for use therein
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
AU3760100A (en) 1999-03-16 2000-10-04 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US6589570B1 (en) 1999-04-12 2003-07-08 University Of Madras Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
CA2370697C (en) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AT275727T (en) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening for modulators of the function of immune stimulatory dna
GB9915204D0 (en) 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
AU774380B2 (en) 1999-08-19 2004-06-24 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
CN100368020C (en) 1999-08-27 2008-02-13 不列颠哥伦比亚大学 Compositions for stimulating cytokine secretion and inducing an immune response
JP2003510282A (en) 1999-09-25 2003-03-18 コーリー ファーマシューティカル ゲーエムベーハー Immunostimulatory nucleic acid
CA2386019C (en) 1999-09-27 2011-06-21 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AT378348T (en) 2000-01-14 2007-11-15 Us Health Oligode oxynucleotides and their use for inducing an immune reaction
AT409085B (en) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh A pharmaceutical composition for immunomodulation and preparation of vaccines
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
EP1414490A1 (en) 2001-08-10 2004-05-06 Dynavax Technologies Corporation Immunomodulatory oligonucleotide formulations and methods for use thereof
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
AU4960901A (en) 2000-03-28 2001-10-08 Univ California Methods for increasing a cytotoxic t lymphocyte response in vivo
EP1278550A4 (en) 2000-04-07 2004-05-12 Univ California Synergistic improvements to polynucleotide vaccines
US20030199466A1 (en) 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
JP4607452B2 (en) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション Immunomodulating composition, formulation and method of use thereof

Similar Documents

Publication Publication Date Title
AU770360C (en) Vaccine composition
AU2001282157A1 (en) Method and device for position determination
AU2001265030A1 (en) Saliva testing and confirmation device
AU2002350109A1 (en) Methods and apparatus for cryo-therapy
AU2001277754A1 (en) Proline derivatives and use thereof as drugs
AU2001296239A1 (en) Gaming device and method
AU2002305450A1 (en) Proteomimetic compounds and methods
AU2001280476A1 (en) Polyaxial connection device and method
AU7101000A (en) Microfabrication methods and devices
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002337953A1 (en) Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
AU2002357119A1 (en) Mitocidal compositions and methods
AU2002335647A1 (en) Methods and devices for electrosurgery
AU2002330943A1 (en) Immunomodulatory compounds and methods of use thereof
DK1261377T3 (en) Immunomodulatory formulations and methods for their use
AU2002351854A1 (en) Ink formulations and uses thereof
AU2001294651A1 (en) Methods and devices for folding and securing tissue
AU3215500A (en) Compounds and methods
AU2001281895A1 (en) Vaccine Composition
AU6416501A (en) Human interface method and apparatus
AU2002245104A1 (en) Topical testosterone formulations and associated methods
AU4046701A (en) Device for fixing earphones and/or mini-microphones
AUPQ676800A0 (en) Dental device
AU2001263361A1 (en) Novel surfactants and formulations